Compare Robinhood Markets, Inc. (HOOD) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Pfizer Inc — how do they compare? Robinhood Markets, Inc. trades at $109.22 (market cap $96.21B), while Pfizer Inc trades at $27.77 (market cap $158.56B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays a 6.18% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Pfizer Inc for 158 Days on average.
| HOOD | PFE | |
|---|---|---|
Market Cap | $96.21B | $158.56B |
Volume | 22,572,153 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $152.46 | $29.02 |
52-Week Low | $65.16 | $23.67 |
Typical Hold Time | 75 Days | 158 Days |
Enterprise Value | $102.75B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $109.51, down 2.22% today, with strong technical support at $108. The stock shows robust fundamentals with 2025 revenue reaching $4.47B and net income of $1.88B, representing 42% margins. Recent news highlights expansion into 24/7 stock trading and new product launches, positioning the company for continued growth in the e-brokerage sector.
Wall Street maintains a bullish outlook with 77% buy ratings and a $137 consensus price target, representing 25% upside potential. Key risks include valuation concerns with a 48.5 P/E ratio and execution challenges in new product rollouts. The company's transformation into a broader financial services platform provides long-term growth opportunities despite near-term volatility.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
